Bayer starts Phase I study with novel targeted radionuclide therapy in advanced metastatic prostate cancer
Indian Pharma Post
by
10h ago
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer ..read more
Visit website
Granules India posts Q4 FY24 consolidated PAT at Rs. 129.64 Cr
Indian Pharma Post
by
10h ago
The company has posted net profit of Rs. 405.31 crores for the Financial Year ended March 31, 2024 ..read more
Visit website
Cipla invests additional Rs. 26 crore in Achira
Indian Pharma Post
by
10h ago
Achira is engaged in development and commercialization of PoC medical test kits in India ..read more
Visit website
Gujarat Themis Biosyn posts Q4 FY24 PAT at Rs. 15.88 Cr
Indian Pharma Post
by
1d ago
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024 ..read more
Visit website
Thyrocare Technologies posts Q4 FY24 consolidated PAT at Rs. 17.78 Cr
Indian Pharma Post
by
1d ago
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024 ..read more
Visit website
IOL Chemicals and Pharmaceuticals posts Q4 FY24 consolidated PAT at Rs. 27.62 Cr
Indian Pharma Post
by
1d ago
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024 ..read more
Visit website
Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr
Indian Pharma Post
by
1d ago
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024 ..read more
Visit website
Bayer Q1 2024 net income drops 8.2% to € 2 billion
Indian Pharma Post
by
2d ago
EBITDA before special items falls 1.3 percent to € 4.41 billion ..read more
Visit website
Coveris invests over €8 million in production capacity
Indian Pharma Post
by
2d ago
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany ..read more
Visit website
Lonza reports softer performance in Q1 2024
Indian Pharma Post
by
2d ago
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s ..read more
Visit website

Follow Indian Pharma Post on FeedSpot

Continue with Google
Continue with Apple
OR